HER2 IHC Interpretation Guide (Examples and Challenging Scenarios)
The Science of HER2-low Breast Cancer and Implications for the Pathology Team
Optimizing the Identification of HER2-Low Breast Cancer
CAP 2022-Breast Workshop
Oncology Today with Dr Neil Love: Optimizing the Identification of HER2-Low Breast Cancer
#BREASTPATH Destiny of HER2/neu in the era of HER2-low in 2024
IBC Research Updates | Dana-Farber IBC Program 2022 Patient Forum
Dr. Aju Mathew, Assistant Professor of Medicine talking on Breast Cancer at our Foster City Lab
Targeting Advanced Triple-Negative Breast Cancer | Dana-Farber Cancer Institute
What Does My Tumor Grade Mean for Breast Cancer? Expert Insights
Key clinical trials investigating immunotherapy in HER2+ and HR+ breast cancer
Pathology of Breast ( Part I ) | Histology of Breast, Clinical Presentations & Breast Anomalies
New Perspectives on the Full Spectrum of HER2 Expression in Breast Cancer
Emerging Strategies in Breast Cancer Care Before, During and After Surgery
What are the grades and stages of breast cancer?
2023 A Practical Approach to Surgical Pathology: Volume IX - A Video CME Teaching Activity
Breast Cancer
Algorithm-assisted assement of HER2 ISH to reduce interobserver variability
HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancer
